Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus
Open Access
- 1 May 2015
- journal article
- clinical trial
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 191 (9), 1040-1049
- https://doi.org/10.1164/rccm.201412-2256oc
Abstract
Rationale: Despite relative antigenic stability, respiratory syncytial virus (RSV) reinfects throughout life. After more than 40 years of research, no effective human vaccine exists and correlates of protection remain poorly defined. Most current vaccine candidates seek to induce high levels of RSV-specific serum neutralizing antibodies, which are associated with reduced RSV-related hospitalization rates in observational studies but may not actually prevent infection. Objectives: To characterize correlates of protection from infection and the generation of RSV-specific humoral memory to promote effective vaccine development. Methods: We inoculated 61 healthy adults with live RSV and studied protection from infection by serum and mucosal antibody. We analyzed RSV-specific peripheral blood plasmablast and memory B-cell frequencies and antibody longevity. Measurements and Main Results: Despite moderately high levels of preexisting serum antibody, 34 (56%) became infected, of whom 23 (68%) developed symptomatic colds. Prior RSV-specific nasal IgA correlated significantly more strongly with protection from polymerase chain reaction–confirmed infection than serum neutralizing antibody. Increases in virus-specific antibody titers were variable and transient in infected subjects but correlated with plasmablasts that peaked around Day 10. During convalescence, only IgG (and no IgA) RSV-specific memory B cells were detectable in peripheral blood. This contrasted with natural influenza infection, in which virus-specific IgA memory B cells were readily recovered. Conclusions: This observed specific defect in IgA memory may partly explain the ability of RSV to cause recurrent symptomatic infections. If so, vaccines able to induce durable RSV-specific IgA responses may be more protective than those generating systemic antibody alone.Keywords
This publication has 51 references indexed in Scilit:
- Kinetics of the Neutralizing Antibody Response to Respiratory Syncytial Virus Infections in a Birth CohortJournal of Medical Virology, 2013
- Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cellsProceedings of the National Academy of Sciences, 2012
- Rapid and Massive Virus-Specific Plasmablast Responses during Acute Dengue Virus Infection in HumansJournal of Virology, 2012
- Follicular Helper CD4 T Cells (TFH)Annual Review of Immunology, 2011
- Immunoglobulin Responses at the Mucosal InterfaceAnnual Review of Immunology, 2011
- Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infectionThe Journal of Experimental Medicine, 2011
- Circulating Antibody‐Secreting Cells during Acute Respiratory Syncytial Virus Infection in AdultsThe Journal of Infectious Diseases, 2010
- Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysisThe Lancet, 2010
- Antigen-Specific Memory B-Cell Responses to Vibrio cholerae O1 Infection in BangladeshInfection and Immunity, 2009
- Rapid cloning of high-affinity human monoclonal antibodies against influenza virusNature, 2008